Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.
Kai-Cheng PengJun-Wei SuZhi XieHan-Min WangMei-Mei FangWen-Feng LiYu-Qing ChenXu-Hui GuanJian SuHong-Hong YanXu Chao ZhangHai-Yan TuQing ZhouHua-Jun ChenYi-Long WuJin-Ji YangPublished in: Thoracic cancer (2022)
EGFR+/METamp + patients treated with first-line TKI monotherapy had poor clinical outcomes. Dual targeted therapy showed potent anticancer activity in the LCO drug testing assay, suggesting that it is a promising first-line treatment for EGFR+/METamp + patients. Randomized controlled trials are needed to further validate these results.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- small cell lung cancer
- end stage renal disease
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- high throughput
- emergency department
- combination therapy
- open label
- single cell
- patient reported
- chronic myeloid leukemia